Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation

Acta Diabetologica

Volumn 52, Issue 2, 2014, Pages 331-336

  Cotugno, M ^a   Nosso, G ^a   Saldalamacchia, G ^a   Vitagliano, G ^a   Griffo, E ^a   Lupoli, R ^a   Angrisani, L ^b   Riccardi, G ^a   Capaldo, B ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b San Giovanni Bosco Hospital   (Italy)

Author keywords

Bariatric surgery; Liraglutide; Type 2 diabetes mellitus; Weight loss

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BARIATRIC SURGERY; BODY MASS; CLINICAL ARTICLE; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT SAFETY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; STOMACH BYPASS; TREATMENT OUTCOME; VERTICAL GASTRECTOMY; VITAMIN DEFICIENCY; VOMITING; WEIGHT REDUCTION; AGED; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; MIDDLE AGED; OBESITY, MORBID; PATHOPHYSIOLOGY;

ADULT; AGED; BARIATRIC SURGERY; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; OBESITY, MORBID; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84925630817     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0644-5     Document Type: Article

References (26)

1. Buchwald H, Estok R, Fahrbach K et al (2009) Weight and type diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122:248–256
2. Dixon JB, Zimmet P, Alberti KG, Rubino F (2011) International diabetes federation taskforce on epidemiology and prevention. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med 28:628–642
3. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H et al (2007) Effects of bariatric surgery on mortality in swedish obese subjects. N Engl J Med 357:741–752
4. Sjöström L (2013) Review of the key results from the Swedish Obese Subjects (SOS) trial: a prospective controlled intervention study of bariatric surgery. J Intern Med 273:219–234
5. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705
6. Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 8:728–742
7. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L (2009) LEAD-6 study group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39–47
8. Fadini GP, Rigato M (2014) Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 7:107–120
9. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596
10. Griffo E, Nosso G, Lupoli R, Cotugno M, Saldalamacchia G, Vitolo G, et al (2013) Early improvement of postprandial lipemia after bariatric surgery in obese type 2 diabetic patients. Obes Surg. [Epub ahead of print]
11. Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM et al (2013) American Association of Clinical Endocrinologists; Obesity Society; American Society for Metabolic and Bariatric Surgery. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient–2013 update cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic and Bariatric Surgery. Obesity (Silver Spring). 21:S1–S27
12. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR (2001) On behalf of the United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 101:671–679
13. MacLean LD, Rhode BM, Sampalis J, Forse RA (1993) Results of the surgical treatment of obesity. Am J Surg 165(1):155–160
14. Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK (2007) Clinical efficacy assessment subcommittee of the american college of physicians. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin a1c targets. A guidance statement from the American College of Physicians. Ann Intern Med 147:417–422
15. Schauer PR, Bhatt DL, Kirwan JP et al (2014) Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes. N Engl J Med 370(21):2002–2013
16. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L et al (2012) Bariatric surgery versus conventional medical therapy for Type 2 diabetes. New Engl J Med 66:1577–1585
17. Ikramuddin S, Korner J, Lee WJ, Connet JE, Inabnet WB III, Billington CJ et al (2013) Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia. JAMA 309:2240–2249
18. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD et al (2014) The STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes: 3-year outcomes. New Engl J Med 370:2002–2013
19. Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G et al (2013) Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomized controlled trials. BMJ 347:f5934
20. Ribaric GL, Buchwald JN, McGlennon TW (2014) Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg 24:437–455
21. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG et al (2011) Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 34:1481–1486
22. Lorber D (2013) GLP-1 Receptor Agonists: Effects on Cardiovascular Risk Reduction. Cardiovasc Ther 31:238–249
23. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH et al (2013) Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 166:823–830
24. Unick JL, Beavers D, Bond DS, Clark JM, Jakicic JM, Kitabchi AE et al (2013) Look AHEAD research group. The long-term effectiveness of a lifestyle intervention in severely obese individuals. Am J Med 126:236–242
25. Salehi M, Gastaldelli A, D’Alessio DA (2014) Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology 146:669
26. Patti ME, Goldfine AB (2010) Hypoglycaemia following gastric bypass surgery–diabetes remission in the extreme? Diabetologia 53:2276–2279